STAT+: Amylyx endocrine drug succeeds in pivotal study — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amylyx Pharmaceuticals said its experimental drug produced a 55% reduction in serious low-blood-sugar events versus placebo in a Phase 3 trial of patients with post-bariatric hypoglycemia (PBH), paving the way for potential approval as the first treatment for the condition.
- The 55% effect exceeded the bar the study was built to clear: it was statistically powered to demonstrate only a 35% improvement over placebo, meaning the trial overshot its prespecified threshold by 20 percentage points.
- Serious hypoglycemic events in the trial are classified as medical emergencies that can involve loss of consciousness or seizures, a severity that frames "any reduction" as highly meaningful for patients and families per Amylyx.
- Justin Klee, co-CEO of Amylyx, called the Phase 3 outcome "so exciting," citing the magnitude of the effect seen in PBH patients who had undergone bariatric surgery.
- The result positions Amylyx for what would be its second approved therapy, targeting a complication of bariatric surgery that currently has no approved treatment option.
- The STAT+ report is gated to subscribers, with the Amylyx data flagged for inclusion in STAT's broader daily biotech roundup (Pharmalittle).
Why it matters: If approved, Amylyx's drug would be the first therapy available for post-bariatric hypoglycemia, a condition with no current standard of care; a Phase 3 that hit 55% versus a 35% powered bar materially de-risks the regulatory filing and expands a small-biotech pipeline beyond Amylyx's ALS drug.
Ask SkimNews
